{
    "nct_id": "NCT04690348",
    "official_title": "Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study",
    "inclusion_criteria": "* Adult patients ≥ 18 years of age who are capable of giving consent\n* Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (>/=95%) resection\n* Karnofsky Performance Status score (KPS) of ≥70\n* Ability to undergo brain MRI with gadolinium\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unable to tolerate MRI or CT imaging\n* Pregnancy (patients must have a negative pregnancy test within 30 days of the operation)\n* Women must agree to not breastfeed for at least 12 weeks after the procedure (lactating and discarding in that interval allowable)\n* Diagnosis of leptomeningeal carcinomatosis or >5 additional active or untreated CNS lesions for a total of >6 active lesions\n* Prior irradiation (EQD2) in excess of 100 Gy to site of implant, using an α/β of 2\n* Apposition of tumor margin to brainstem or optic apparatus\n* Previous infection within the operative field, current active systemic infection requiring systemic therapy, or immunodeficiency\n* Urgent surgery required prior to availability of brachytherapy\n\nIntraoperative Exclusion Criterion:\n\n* Patients will be excluded if intraoperative pathology is not consistent with >/=5% viable metastatic disease.",
    "miscellaneous_criteria": ""
}